Organisation paid for research Program year 2024 Source: CMS Open Payments

Nsabp Foundation Inc

Neither a doctor nor a teaching hospital

Research payments

$49,129,138

51 payments

Through program year 2024, Nsabp Foundation Inc is reported as receiving $49,129,138 in research payments, across 51 payments.

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$6,405,440	5
2023	Research	$16,713,368	3
2022	Research	$24,584,291	28
2021	Research	$160,000	1
2020	Research	$333,642	6
2019	Research	$932,397	8

Breakdown

Who paid Research payments · program years 2019–2024

Genentech, Inc. $46,745,731 17 payments
Merck Sharp & Dohme Corporation $1,506,039 17 payments
Roche Products Limited $866,994 3 payments
Pfizer Inc. $10,375 14 payments

Studies the money was for Research payments · program years 2019–2024

Nsabp Protocol B 59 GBG 96 Gepardouze $44,662,823 11 payments
A Randomized Phase III Trial of A Randomized, Double-Blind, Phase III Trial of Paclitaxeltrastuzumab Pertuzumab With Atezolizumab Or Placebo in First Line Her2-Positive Metastatic Breast Cancer $1,138,377 2 payments
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with 1 cm Residual Invasive Cancer or Positive Lymph Nodes pN1mic After Neoadjuvant Chemotherapy $1,098,600 14 payments
T Dm1 High Risk Ebc PTS With Residual Inv Disease $866,994 3 payments
Her2 Invasive Node Or High Risk Node $750,288 2 payments
A phase Ib study of pembrolizumab in combination with pemetrexed and oxaliplatin in subjects with chemo-refractory metastatic colorectal cancer $407,439 3 payments
Folfox Bevacizumab Combination Chemotherapy With Or Without Atezolizumab $194,242 2 payments
Pallaspalbociclib Collaborative Adjuvant Studya Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for HR Or Her2 Early Breast Cance $10,375 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.